Table 2. History of KGOG-SGOG Joint Meetings.
| KGOG-SGOG meeting | Attendee | Agenda |
|---|---|---|
| 1st KGOG-SGOG (June 13, 2012, Seoul, Korea) | KGOG member: Joo-Hyun Nam, Jae-Weon Kim, Jae-Hoon Kim, Byoung-Gie Kim, Sang-Young Ryu, Sokbom Kang, Dong Hoon Suh, Yoo-Kyung Lee SGOG member: Rongyu Zang |
Introduction of KGOG and SGOG (Jae-Hoon Kim) |
| KGOG 2014, 2015 (Sokbom Kang) | ||
| KGOG 3019 (Byoung-Gie Kim) | ||
| SGOG ongoing trials and related activities (Rongyu Zang) | ||
| GOG263, TACO (Sang-Young Ryu) | ||
| 2nd SGOG-KGOG (December 8, 2012, Shanghai, China) | SGOG member: Jing-He Lang, Rongyu Zang, Wen Di, Ji-Hong Liu, Xian-Jie Tan, Quan Hao, Xiaojun Chen, Xi Cheng, Xi-Peng Wang, Boer Shan, Xiao Huang, Bei-Hua Kong, Xiao-Ping Wan, Hong Sun, Yin-Cheng Teng, Jianqing Zhu, Ping Zhang, Hua Jiang, Ya-Ping Zhu, Li-Hua Qiu, Jin-jin Yu, Zhi-Yuan Dai, Xia Wu, Ting-Yan Shi, Shu Shan KGOG member: Soon-Beom Kang, Jae-Hoon Kim, Jae-Weon Kim, Sang-Young Ryu, Dong Hoon Suh |
Ovarian cancer trials and translational research within SGOG (Rongyu Zang) |
| Ovarian cancer trials and translational research of KGOG (Jae-Hoon Kim) | ||
| Introduction of Peking Union Medical College Hospital (Xian-Jie Tan) | ||
| International clinical trials on cervical cancer and TACO trial (Sang-Young Ryu) | ||
| Metabolic syndrome and endometrial cancer (Xiao-Jun Chen) | ||
| Prospective observational study for the validation of preoperative low-risk criteria for LN metastasis in endometrial cancer (Jae-Weon Kim) | ||
| Data flow in KGOG trials and e-Velos system (Dong Hoon Suh) | ||
| Post-GWAS collaborations of ovarian cancer (Ting-Yan Shi) | ||
| 3rd SGOG-KGOG (September 19–20, 2014, Shanghai, China) | SGOG member: Jie Jiang, Heng Cui, Jihong Liu, Xiu-Gui Sheng, Jianqing Zhu, Ping Zhang, Wen Gao, Hong Pu, Xiaojun Chen, Xin Lu, Xi-Peng Wang, Yaping Zhu, Zhi-Yuan Dai, Hua-Ying Wang, Xiao Huang, Yan-Fei Liu, Rongyu Zang, Jun Guan, Rong Jiang, Bing-Yi Yang, Ting-Yan Shi, Yun-Lang Cai, Chun-Lin Chen KGOG member: Joo-Hyun Nam, Byoung-Gie Kim, Jae-Hoon Kim, Jae-Weon Kim, Sokbom Kang, Sang-Young Ryu |
KGOG 1029 (Joo-Hyun Nam) |
| SGOG OV2 (SMART2) (Rong Jiang) | ||
| KGOG TACO (Sang-Young Ryu) | ||
| SGOG OV1 (SMART1) (Rong Jiang) | ||
| SGOG SMART1 phase II to phase III (Rong Jiang) | ||
| SGOG OV3, OV4A, OV4B (Rongyu Zang) | ||
| KGOG2015 (Sokbom Kang) | ||
| ECCO and SGOG possible participators (Byoung-Gie Kim) | ||
| SGOG-KGOG Cooperation Concept (Byoung-Gie Kim, Rongyu Zang) | ||
| 4th KGOG-SGOG (November 12, 2015, Seoul, Korea) | KGOG member: Soon-Beom Kang, Joo-Hyun Nam, Byoung-Gie Kim, Jae-Hoon Kim, Jae-Weon Kim, Sang-Young Ryu, Sang-Wun Kim, Dong Hoon Suh, Jeong-Yeol Park, Yoo-Young Lee SGOG member: Rongyu Zang, Xiaojun Chen, Xi-Peng Wang, Ji-Hong Liu |
SOTO study, searching an optimal third-line chemo+/− anti-angiogenic therapy in ovarian cancer (Sang-Wun Kim) |
| The SUNNY trial, a phase 3 randomized study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery in ovarian cancer (Rongyu Zang) | ||
| Phase II study of fertility-sparing management using high-dose oral progestin in young women with stage I endometrial adenocarcinoma, grade 2 or superficial myometrial invasion (Jeong-Yeol Park) | ||
| The effect of metformin combined with megestrol acetate in conservative treatment of early stage endometrial cancer and endometrial atypical hyperplasia: a multicenter randomized control trial (Xiaojun Chen) |
ECCO, European Cancer Organisation; GOG, Gynecologic Oncology Group; GWAS, genome-wide association study; KGOG, Korean Gynecologic Oncology Group; LN, lymph node; OV, ovary; SGOG, Shanghai Gynecologic Oncology Group; SOTO, searching an optimal chemo/anti-angiogenic therapy in platinum resistant ovarian cancer; SUNNY, study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage iiic and iv ovarian cancer; SMART1, a phase ii, randomized study of an addition intraperitoneal cisplatin and etoposide to standard first-line therapy in stage IIIC and stage IV epithelial ovarian, fallopian tube and primary peritoneal cancer; SMART2, a phase II/III study to evaluate the efficacy of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer; TACO, tri-weekly administration of cisplatin in locally advanced cervical cancer study.